![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Gidazepam IC |
Routes of administration | Oral |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Hepatic |
Elimination half-life | ~87 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H15BrN4O2 |
Molar mass | 387.237 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Gidazepam, also known as hydazepam or hidazepam, [2] is a drug which is an atypical benzodiazepine derivative, developed in the Soviet Union. [3] [4] It is a selectively anxiolytic benzodiazepine. [5] It also has therapeutic value in the management of certain cardiovascular disorders. [6] [7] [8] [9] [10]
Gidazepam and several of its analogs, in contrast to other benzodiazepines, are comparatively more selective agonists of TSPO (formerly the peripheral benzodiazepine receptor) than the benzodiazepine receptor. [5]
Gidazepam acts as a prodrug to its active metabolite 7-bromo-2,3-dihydro-5-phenyl-1H-1,4-benzodiazepin-2-one (desalkylgidazepam or bromo-nordazepam). [11] [12] Its anxiolytic effects can take several hours to manifest presumably due to its slow metabolism (half-life 87 hours). The onset and intensity of anxiolytic effects correlate with blood levels of desalkylgidazepam. [13]